Mouse genomic screen reveals novel host regulator of metastasis by unknown
Celià-Terrassa and Kang Genome Biology  (2017) 18:31 
DOI 10.1186/s13059-017-1170-xRESEARCH HIGHLIGHT Open AccessMouse genomic screen reveals novel host
regulator of metastasis
Toni Celià-Terrassa and Yibin Kang*Abstract
Tumor cells have to overcome challenges in the host
tissue microenvironment to metastasize successfully to
distant organs. In a recent Nature study, a genome-wide
functional screen demonstrated that deficiency of the
sphingosine-1-phoshate (S1P) transporter gene Spns2 in
endothelium increased immune-mediated cell killing by
T cells and natural killer (NK) cells, thereby suppressing
metastatic colonization.cell killing [6]. Interestingly, previous studies also indicateMetastasis is a highly inefficient process—less than 0.02%
of disseminated tumor cells (DTCs) are believed to be
capable of seeding secondary tumors. Much of the high
rate of attrition of DTCs occurs during the colonization
step, where the arriving DTCs face a challenging micro-
environment that is often distinctively different from that
of the primary tumor [1]. Application of transcriptomic
profiling and genome-wide functional screening strategies
based on RNA interference, CRISPR-Cas9 genome edit-
ing, or transposon mutagenesis technologies have led to
the discovery of various tumor-cell-intrinsic factors that
are important for successful metastatic colonization in
various target organs [1]. Pioneering work by Hunter
and others using mouse genetic crossing has also re-
vealed the critical role of the host genetic background
in determining metastatic efficiency [2]. However, gen-
etic screening of host tissue regulators of metastasis
has been difficult and rarely attempted previously. In a
recent issue of Nature, van der Weyden and colleagues
used 810 mutant mouse strains to conduct a tour de
force in vivo screen of host genes involved in regulating
metastatic colonization [3]. The study revealed that
deficiency of Spns2, which encodes a transporter of
sphingosine-1-phoshate (S1P) that regulates lympho-
cyte trafficking, strongly suppressed lung metastasis* Correspondence: ykang@princeton.edu
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ural killer (NK)-cell-mediated immune defense present
at distant organs.
A major hurdle for successful metastatic colonization of
DTCs is the host tissue immune system [1]. It has been
shown that cytotoxic T cells are critical for preventing
metastatic colonization of melanoma in the lungs [4], and
that NK cell depletion increases metastasis [5]. Metastatic
cancer cells have been reported to develop mechanisms to
suppress the host immune system [1] or evade immune
that host tissue polymorphisms can alter the risk of cancer
metastasis by affecting immune surveillance of cancer.
For example, Cadm1 is a metastasis susceptibility locus
gene that suppresses metastasis by sensitizing tumor
cells to T-cell-mediated killing [7].
In the Nature study, the authors tested lung metas-
tasis efficiency of the B16-F10 metastatic mouse mel-
anoma cell line in 810 randomly selected mutant
mouse strains that are defective in genes involved in a
wide range of biological functions. They identified 23
host mutations that significantly decreased or in-
creased the number of lung metastatic lesions. Inter-
estingly, 19 out of these 23 mutant mouse strains
displayed immune-related phenotypes, which implied
a prominent involvement of the host immune system
in regulating metastatic colonization. Not surprisingly,
mutations that caused deficiency in the interferon re-
sponse, such as loss of the interferon regulatory factor
genes Irf1 and Irf7, resulted in an increased incidence
of metastasis. On the other hand, mutations in 15
genes, including many that have not previously been
implicated in metastasis, reduced the rate of metasta-
sis. The strongest metastatic suppression was observed
in the Spns2tm1a/tm1a mutant mouse strain. While pri-
mary tumor growth was not affected in Spns2 mutant
mice, spontaneous and experimental metastasis to
lung and liver was reduced when they were injected
with metastatic melanoma, colorectal, or breast cancer
cell lines. Importantly, although Spns2 mutation didle is distributed under the terms of the Creative Commons Attribution 4.0
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cancer cells, an increased number of apoptotic cancer cells
were observed in the lung. These findings indicate that
host SPNS2 fosters a more favorable environment for the
survival of DTCs in the lung.
SPNS2 is a cell surface protein that transports intracel-
lular S1P to blood and lymph, where S1P acts as a bio-
active lipid mediator that binds to its G-protein-coupled
receptor to regulate cell survival, proliferation, migra-
tion, angiogenesis, lymphangiogenesis, lymphocyte traf-
ficking, and immune response [8]. Consistent with the
critical role of SPNS2 in S1P transport, Spns2tm1a/tm1a
mice have lower levels of S1P in serum and increased
levels in the lung, which resulted in a profound alter-
ation of leukocyte trafficking in the animals. In addition
to a significant reduction of T and B cells in circulation,
a dramatic increase in the NK-cell population and a re-
duced T-cell percentage were observed in the lungs of
Spns2tm1a/tm1a mice.
The authors used bone marrow transplantation experi-
ments to conclude that a non-hematopoietic stromal
component controls the Spns2-mediated phenotype in
leukocyte trafficking and metastasis. As an S1P gradient
in lymph has been reported to be crucial for regulating
lymphocyte circulation, the researchers focused their in-
vestigation on the lymphatic endothelium. Indeed, mice
with lymphatic-endothelial-cell-specific deletion of Spns2
(Spns2tm1a/tm1a; Lyve1cre/+) showed decreased lympho-
cyte counts in the blood, lungs, and other tissues, and















Fig. 1 Endothelial SPNS2 regulates lymphocyte trafficking to influence met
following dissemination through vascular or lymphatic systems, cancer cell
defenses. In wild-type mice (left panel), the S1P transporter SPNS2 regulates
homeostasis as well as organ regulatory T (Treg) cells. In this scenario, the Treg
highly metastatic tumor cells. However, in the Spns2-deficient mice (Spns2tm1a
the lungs, disrupting lymphocyte trafficking. This results in an increased ratio
prevents metastatic colonization of arriving cancer cellscells (Fig. 1). These findings indicate that Spns2 deficiency
in lymphatic endothelium alters the immune microenvir-
onment of the lungs and possibly other organs to reduce
metastatic colonization.
At first glance, it seems counterintuitive that a decreased
lymphocyte count weakens metastatic colonization. How-
ever, the authors went on to demonstrate that despite a
general decrease in T cells, the ratio of effector T cells
and immunosuppressive regulatory T (Treg) cells was
increased in the lungs of Spns2-deficient mice, as were
NK cell numbers. In addition, CD4+ and CD8+ cells
from Spns2tm1a/tm1a animals showed a stronger de-
granulation response, increased interferon-γ production,
and more effective B16-F10 tumor cell killing in vitro, in-
dicating higher T-cell activity. In vivo T-cell and NK-cell
depletion experiments showed that combined depletion of
CD8+ T cells and NK cells, but not either population
alone, restored the metastatic efficiency of cancer cells in
Spns2tm1a/tm1a mice to the levels observed in wild-type
mice. Similar findings were observed in the liver, demon-
strating that both T cells and NK cells are responsible for
and work cooperatively to provide defense against metas-
tasis in different organs. Finally, treatment of wild-type
mice with 4′-deoxypyridoxine (DOP), which inhibits S1P
degradation and thus increases S1P levels, led to a similar
increase in immune-mediated killing and suppression of
lung metastasis as observed in the Spns2tm1a/tm1a mice.
This result indicates that S1P levels regulate lymphocyte
circulation and modulate the percentage of effector T cells
and NK cells in the lung, thereby offering an attractiveS1P
NK cells
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astatic colonization. After extravasation into the lung parenchyma
s normally encounter a hostile environment dominated by immune
the circulation levels of S1P and maintains lymphocyte trafficking
cells are abundant in the lung tissue, which facilitates the colonization of
/tm1a; right panel), S1P levels are decreased in circulation but are higher in
of cytotoxic CD8+ T cells and natural killer (NK) cells in the lungs, which
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(Fig. 1).
While previous research in the field had revealed in-
tricate networks of tumor–stromal interactions during
metastasis, the current study represents the first extensive
in vivo screen of host factors that influence metastatic
colonization. Several other genes identified in the screen
still remained uncharacterized for their functional mech-
anism in metastasis, representing many additional avenues
for future explorations. Further efforts on similar in vivo
functional screens should focus on “druggable” classes of
genes with no life-threatening phenotypes in mutant
mice, as these genes are likely ideal targets for therapeutic
intervention.
Consistent with the findings observed in mouse
models, SPNS2 has been reported to be upregulated in
the stromal gene expression signature associated with a
poor clinical outcome of human breast cancer [9],
which underscores the clinical relevance of the present
study. The identification of SPNS2 as a novel regulator
of the host immune response to metastasis further
highlights the essential role of resident immune cells in
guarding and protecting against metastasis. The rele-
vance of this mechanism is particularly salient, as im-
munotherapy has been proven to have striking effects
in metastatic cancer patients, especially in those with
metastatic melanoma [10]. It is unclear why SPNS2
deficiency specifically affects the development of metas-
tases but has no impact on primary tumor growth. It is
possible that initial metastatic seeding is particularly
sensitive to immune clearance, while established tu-
mors are more refractory to the attack of effector T
cells and NK cells. Alternatively, the immune micro-
environment in the lung and other organs may be more
responsive to S1P levels. Future studies need to investi-
gate these questions, and explore the therapeutic effect
of S1P and SPNS2 inhibition in established metastasis,
which more closely mimics the clinical situation of
late-stage cancer patients.
There are several potential translational applications
of these new insights into SPNS2 and S1P as functional
regulators of metastasis. As circulating S1P levels are
tightly controlled by SPNS2, and increasing S1P levels
with DOP treatment can suppress metastasis, S1P could
be used as a biomarker of metastasis susceptibility in
cancer patients. Such analysis should be performed
after stratifying patients based on their cancer subtypes,
as varying degrees of immune infiltration have been re-
ported in different subtypes of breast cancer and other
cancers. Targeting S1P using blocking antibodies such
as sphingomab could be complicated by potential side
effects in the immune and vascular systems. Alternatively,
because it is a cell surface transporter, neutralizing
antibodies or small inhibitors against SPNS2 could bedeveloped as agents to prevent or reduce metastasis. In
addition, genetic polymorphism, somatic mutations, or
other means of increased expression or activity of SPNS2
and other components of the S1P pathway may play a
causal role in promoting cancer metastasis, which should
be an important topic for future investigations. Overall,
this study represents a novel approach to study the com-
plicated role of host tissue in cancer metastasis and opens
up a potential new avenue to increase the efficacy of im-
munotherapy for metastatic cancer.
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